RespireRx Pharmaceuticals Inc. Announces Preliminary Top-Line Analysis of Data from Duke University Phase 2A Clinical Trial of CX1739
Glen Rock, N.J., September 12, 2016/Globe Newswire – RespireRx Pharmaceuticals Inc. (OTCQB: RSPID and OTCQB: RSPI) (“RespireRx” or the “Company”) is a leader in the development of medicines for respiratory disorders, including drug-induced respiratory depression (RD) and sleep apneas. RespireRx is today reporting preliminary top-line data from its Phase 2A clinical trial of CX1739, the…
RespireRx Pharmaceuticals Inc. to Present at the Rodman & Renshaw 18th Annual Global Investment Conference on September 12, 2016
Glen Rock, N.J., September 8, 2016/Globe Newswire – RespireRx Pharmaceuticals Inc. (OTC QB: RSPI) (“RespireRx” or the “Company”), a leader in the development of medicines for respiratory disorders, including drug-induced respiratory depression and sleep apneas, announced that the Company’s President, CEO and Vice Chairman of the Board of Directors, James S. Manuso, Ph.D., will present…
RespireRx Pharmaceuticals Inc. Announces 1-for-325 Reverse Stock Split
Glen Rock, N.J., September 1, 2016/Globe Newswire – RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the development of medicines for respiratory disorders, including sleep apneas and drug-induced respiratory depression, today announced that the Company is effecting the one-for-three-hundred–twenty-five reverse stock split of the Company’s issued and outstanding common stock (the…
RespireRx Pharmaceuticals Inc. Files June 30, 2016 Quarterly Report on Form 10-Q
Glen Rock, N.J., August 15, 2016/Globe Newswire – RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the development of medicines for respiratory disorders, including sleep apneas and drug-induced respiratory depression, has filed its June 30, 2016 Quarterly Report on Form 10-Q and is hereby providing an update on the Company’s ongoing…
RespireRx Pharmaceuticals Inc. to Present at the Cantor Fitzgerald 2nd Annual Healthcare Conference on July 13, 2016
Glen Rock, N.J., July 12, 2016/Globe Newswire – RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the development of medicines for respiratory disorders, including sleep apneas and drug-induced respiratory depression, announced that the Company’s President, CEO and Vice Chairman of the Board of Directors, James S. Manuso, Ph.D., will present at…
RespireRx Pharmaceuticals Inc. to Present at the Jefferies 2016 Healthcare Conference
Glen Rock, N.J., June 8, 2016/Globe Newswire – RespireRx Pharmaceuticals Inc. (OTC QB: RSPI) (“RespireRx” or the “Company”), a leader in the development of medicines for respiratory disorders, including sleep apneas and drug-induced respiratory depression, announced that the Company’s President, CEO and Vice Chairman of the Board of Directors, James S. Manuso, Ph.D., will present…
RespireRx Pharmaceuticals Inc. Files March 31, 2016 Quarterly Report on Form 10-Q
Glen Rock, N.J., May 16, 2016/Globe Newswire – RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the development of medicines for respiratory disorders, including sleep apneas and drug-induced respiratory depression, has filed its March 31, 2016 Quarterly Report on Form 10-Q and is hereby providing an update on the Company’s ongoing…
RespireRx Pharmaceuticals Inc., the University of Alberta and the University of Florida Provide Update on Collaborative Research Activities
Use of Ampakines as a Novel Therapy for Overcoming Central Respiratory Depression Glen Rock, N.J., April 1, 2016/Globe Newswire – RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the development of medicines for respiratory disorders, including sleep apneas and drug-induced respiratory depression, is providing an update on the Company’s collaborative research…